35 min listen
BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez
BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez
ratings:
Length:
34 minutes
Released:
Feb 20, 2023
Format:
Podcast episode
Description
SPECIAL EDITION: BOB@JPMBolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr. Perez at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Feb 20, 2023
Format:
Podcast episode
Titles in the series (100)
Summer Sessions 1: Ivor Macleod brings big-league finance experience to an emerging biotech by Business Of Biotech